Is Celcuity (CELC) Cheap After Its REVTORPYK Launch?

Celcuity (CELC) has entered a new phase, with REVTORPYK now commercially available in the United States for certain HR+/HER2- advanced breast cancer patients following prior endocrine treatment.

Celcuity’s recent FDA approval and US launch of REVTORPYK come after a stretch where momentum has cooled in the near term, with the 30-day share price return down 13.55% and the 90-day share price return down 26.34%, even as the 1-year total shareholder return of 60.91% and very large 3-year total shareholder return point to a stock that has already moved a long way on earlier expectations.

Scan beyond Celcuity and review other healthcare and biotech opportunities using the hand picked 36 healthcare AI stocks that may be preparing for their next significant move.

Celcuity now has an approved drug on the market, yet the recent pullback suggests sentiment has cooled after a very strong multi year run. Does the current valuation still match what this business is today?

Most Popular Narrative: 51% Undervalued

Celcuity’s most followed valuation story points to a fair value of about $161 per share versus the last close at $79.52, so the current quote sits well below where that framework lands.

Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.

See why 5 investors see Celcuity as 51% undervalued.

Result: Fair Value of $161.09 (UNDERVALUED)

Still, if upcoming clinical data underwhelms or regulators demand more evidence, the bullish Celcuity narrative could unravel and push expectations sharply lower.

Find out about the key risks to this Celcuity narrative.

Next Steps

Sentiment around Celcuity is clearly mixed right now, so consider acting promptly, review the details for yourself, and weigh both sides of the story with the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Celcuity?

If Celcuity has your attention, do not stop here. Broaden your watchlist, compare different risk profiles, and pressure test your thesis against fresh opportunities.

• Target resilient income by scanning companies with strong payouts and balance sheets using the 7 dividend fortresses.
• Spot quality at a potential discount by reviewing the 31 high quality undervalued stocks that combine fundamentals with appealing pricing.
• Unearth underfollowed potential by checking the 19 high quality undiscovered gems before the wider market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com